FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137564209> ?p ?o ?g. }

• W2137564209 endingPage "41" @default.
• W2137564209 startingPage "35" @default.
• W2137564209 abstract "Epidermal growth factor receptor 1 (EGFR 1 ) is a 170-kd glycoprotein that plays many roles in the growth of non-small cell lung cancer (NSCLC). There are four known receptors in the EGFR family. Binding of a ligand such as epidermal growth factor (EGF) or transforming growth factor-alpha (TGF-alpha) causes EGFR to undergo a conformational change leading to autophosphorylation of EGFR and activation of the EGFR growth factor pathway. The protein products of the genes that are then expressed increase cell proliferation and angiogenesis and inhibit programmed cell death. EGFR is expressed in 40% to 80% of NSCLC. EGFR tyrosine kinase activity can be inhibited by antibody therapy, such as cetuximab, against the extracellular domain of EGFR or small-molecule therapy, such as gefitinib or erlotinib that blocks the adenosine triphosphate (ATP) binding site of the cytoplasmic domain. Both forms of EGFR inhibition have single-agent antitumor activity against previously treated NSCLC. Interestingly, EGFR expression does not correlate with response to EGFR inhibition therapy. Increased likelihood of responding to small-molecule therapy is associated with female gender, never smoking, adenocarcinoma, and acquired mutations of the EGFR ATP binding site in tumor cells. In previously treated NSCLC, the small-molecule erlotinib improved both quality of life and median survival as a single agent compared with best supportive care. Southwest Oncology Group 0023 is a large, phase III, randomized trial comparing concurrent chemoradiotherapy and consolidation docetaxel with or without maintenance small-molecule therapy with gefitinib. There is also strong preclinical evidence that EGFR inhibition is additive or synergistic with radiotherapy in NSCLC. In locally advanced head and neck cancer, the addition of cetuximab antibody therapy to radiation increased median survival from 28 to 54 months. Cancer and Leukemia Group B 30106 and a multi-institutional Australian phase I trial have shown that gefitinib can be added to concurrent chemoradiotherapy for stage III NSCLC without excessive toxicity. A phase I trial at the University of Chicago (Chicago, IL) has evaluated erlotinib with concurrent chemoradiotherapy in stage III NSCLC. Radiation Therapy Oncology Group 0324 is an on-going phase II trial studying cetuximab and concurrent chemoradiotherapy in stage III NSCLC." @default.
• W2137564209 created "2016-06-24" @default.
• W2137564209 creator A5079438136 @default.
• W2137564209 date "2005-04-01" @default.
• W2137564209 modified "2023-09-27" @default.
• W2137564209 title "Inhibition of the Epidermal Growth Factor Receptor in Combined Modality Treatment for Locally Advanced Non-Small Cell Lung Cancer" @default.
• W2137564209 cites W1490790087 @default.
• W2137564209 cites W165992630 @default.
• W2137564209 cites W1814699096 @default.
• W2137564209 cites W1969257771 @default.
• W2137564209 cites W2036926586 @default.
• W2137564209 cites W2043696829 @default.
• W2137564209 cites W2073464554 @default.
• W2137564209 cites W2110835998 @default.
• W2137564209 cites W2111710483 @default.
• W2137564209 cites W2116036462 @default.
• W2137564209 cites W2120718661 @default.
• W2137564209 cites W2122314043 @default.
• W2137564209 cites W2122712858 @default.
• W2137564209 cites W2123967535 @default.
• W2137564209 cites W2126314379 @default.
• W2137564209 cites W2127101185 @default.
• W2137564209 cites W2146404049 @default.
• W2137564209 cites W2161821474 @default.
• W2137564209 cites W2201485991 @default.
• W2137564209 cites W2222261101 @default.
• W2137564209 cites W2244058194 @default.
• W2137564209 cites W2249645282 @default.
• W2137564209 cites W2255070730 @default.
• W2137564209 cites W2263676542 @default.
• W2137564209 cites W2270865219 @default.
• W2137564209 cites W2273429638 @default.
• W2137564209 cites W2278057905 @default.
• W2137564209 cites W2343670117 @default.
• W2137564209 cites W2596354356 @default.
• W2137564209 doi "https://doi.org/10.1053/j.seminoncol.2005.03.008" @default.
• W2137564209 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16015534" @default.
• W2137564209 hasPublicationYear "2005" @default.
• W2137564209 type Work @default.
• W2137564209 sameAs 2137564209 @default.
• W2137564209 citedByCount "15" @default.
• W2137564209 countsByYear W21375642092014 @default.
• W2137564209 crossrefType "journal-article" @default.
• W2137564209 hasAuthorship W2137564209A5079438136 @default.
• W2137564209 hasConcept C121608353 @default.
• W2137564209 hasConcept C126322002 @default.
• W2137564209 hasConcept C130287650 @default.
• W2137564209 hasConcept C143998085 @default.
• W2137564209 hasConcept C170493617 @default.
• W2137564209 hasConcept C2776256026 @default.
• W2137564209 hasConcept C2776362946 @default.
• W2137564209 hasConcept C2777506169 @default.
• W2137564209 hasConcept C2778087573 @default.
• W2137564209 hasConcept C2779438470 @default.
• W2137564209 hasConcept C2780580887 @default.
• W2137564209 hasConcept C2780586478 @default.
• W2137564209 hasConcept C42362537 @default.
• W2137564209 hasConcept C502942594 @default.
• W2137564209 hasConcept C71924100 @default.
• W2137564209 hasConceptScore W2137564209C121608353 @default.
• W2137564209 hasConceptScore W2137564209C126322002 @default.
• W2137564209 hasConceptScore W2137564209C130287650 @default.
• W2137564209 hasConceptScore W2137564209C143998085 @default.
• W2137564209 hasConceptScore W2137564209C170493617 @default.
• W2137564209 hasConceptScore W2137564209C2776256026 @default.
• W2137564209 hasConceptScore W2137564209C2776362946 @default.
• W2137564209 hasConceptScore W2137564209C2777506169 @default.
• W2137564209 hasConceptScore W2137564209C2778087573 @default.
• W2137564209 hasConceptScore W2137564209C2779438470 @default.
• W2137564209 hasConceptScore W2137564209C2780580887 @default.
• W2137564209 hasConceptScore W2137564209C2780586478 @default.
• W2137564209 hasConceptScore W2137564209C42362537 @default.
• W2137564209 hasConceptScore W2137564209C502942594 @default.
• W2137564209 hasConceptScore W2137564209C71924100 @default.
• W2137564209 hasLocation W21375642091 @default.
• W2137564209 hasLocation W21375642092 @default.
• W2137564209 hasOpenAccess W2137564209 @default.
• W2137564209 hasPrimaryLocation W21375642091 @default.
• W2137564209 hasRelatedWork W2025029856 @default.
• W2137564209 hasRelatedWork W2049303357 @default.
• W2137564209 hasRelatedWork W2135761436 @default.
• W2137564209 hasRelatedWork W2137564209 @default.
• W2137564209 hasRelatedWork W2139819066 @default.
• W2137564209 hasRelatedWork W2140452388 @default.
• W2137564209 hasRelatedWork W2167157100 @default.
• W2137564209 hasRelatedWork W2325071936 @default.
• W2137564209 hasRelatedWork W3029235022 @default.
• W2137564209 hasRelatedWork W3042289395 @default.
• W2137564209 hasVolume "32" @default.
• W2137564209 isParatext "false" @default.
• W2137564209 isRetracted "false" @default.
• W2137564209 magId "2137564209" @default.
• W2137564209 workType "article" @default.